| Literature DB >> 25659473 |
Preethi Premkumar1, Dominic Fannon2, Adegboyega Sapara2, Emmanuelle R Peters3, Anantha P Anilkumar4, Andrew Simmons5, Elizabeth Kuipers3, Veena Kumari3.
Abstract
Grey matter volume (GMV) in the orbitofrontal cortex (OFC) may relate to better response to cognitive behavioural therapy for psychosis (CBTp) because of the region׳s role in emotional decision-making and cognitive flexibility. This study aimed to determine the relation between pre-therapy OFC GMV or asymmetry, emotional decision-making and CBTp responsiveness. Emotional decision-making was measured by the Iowa Gambling task (IGT). Thirty patients received CBTp+standard care (CBTp+SC; 25 completers) for 6-8 months. All patients (before receiving CBTp) and 25 healthy participants underwent structural magnetic resonance imaging. Patients׳ symptoms were assessed before and after therapy. Pre-therapy OFC GMV was measured using a region-of-interest approach, and IGT performance was measured as overall learning, attention to reward, memory for past outcomes and choice consistency. Both these measures, were comparable between patient and healthy groups. In the CBTp+SC group, greater OFC GMV correlated with positive symptom improvement, specifically hallucinations and persecution. Greater rightward OFC asymmetry correlated with improvement in several negative and general psychopathology symptoms. Greater left OFC GMV was associated with lower IGT attention to reward. The findings suggest that greater OFC volume and rightward asymmetry, which maintain the OFC׳s function in emotional decision-making and cognitive flexibility, are beneficial for CBTp responsiveness.Entities:
Keywords: Asymmetry; Prefrontal cortex; Schizophrenia
Mesh:
Year: 2015 PMID: 25659473 PMCID: PMC4834460 DOI: 10.1016/j.pscychresns.2015.01.013
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222
Fig. 1Rating of OFC grey matter as seen in the coronal, sagittal and axial views at two stereological points.
Demographic, pre-therapy orbitofrontal cortex grey matter volume, pre- and post-therapy PANSS symptoms, and pre-therapy neuropsychological performance (mean, S.D. and range) in CBTp+SC patients (n=25) and healthy participants (n=25).
| Characteristic | CBTp+SC patients | Healthy participants | Model | ||||
|---|---|---|---|---|---|---|---|
| Sex: male/female ( | 17/8 | 17/8 | Group | ||||
| Age in years | 35.56, 8.11, 21–49 | 33.72, 12.64, 20–65 | Group | 0.62 (1,48) | 0.43 | ||
| Years in education | 13.88, 3.07, 8–20 | 15.08, 2.46, 10–20 | Group | 1.86 (1,48) | 0.18 | ||
| Edinburgh Handedness Inventory | 9.42, 1.09, 6–10.0 | 8.64, 1.40, 5.5–10.0 | Group | 3.22 (1,48) | 0.18 | ||
| Grooved pegboard test | Dominant | Non-dominant | Dominant | Non-dominant | |||
| 76.04, 19.57, 5.00–110.62 | 87.14, 21.66, 6.20–111.27 | 63.41, 13.96, 49.24–120.09 | 76.22, 20.80, 46.63–117.85 | Hand×Group | 0.13 (1,48) | 0.71 | |
| Total OFC GMV (cm3) | 17.17, 4.43, 10.44–24.40 | 19.66, 6.73, 9.25–33.85 | Group | 3.77 (2) | 0.15 | ||
| Left OFC GMV (cm3) | 8.54, 2.10, 4.74–12.19 | 9.43, 3.50, 3.96–16.81 | |||||
| Right OFC GMV (cm3) | 8.70, 2.66, 4.44–14.26 | 10.23, 3.34, 4.82–17.57 | Hemisphere×Group | 1.92 (2,66) | 0.15 | ||
| Symptoms (PANSS) | Baseline | Follow-up | |||||
| Positive | 18.08, 4.78, 7–25 | 14.84, 4.17, 7–23 | - | Time | 14.11 (1,24) | 0.001 | |
| Negative | 17.88, 4.37, 8–27 | 15.48, 4.20, 8–24 | - | Time | 9.61 (1,24) | 0.005 | |
| General psychopathology | 33.16, 7.18, 22–56 | 28.32, 7.14, 16–41 | - | Time | 9.93 (1,24) | 0.004 | |
| Total | 69.12, 13.61, 43–108 | 58.64, 14.49, 31–78 | - | Time | 15.2 (1,24) | 0.001 | |
| IGT overall learning | 7.81, 16.61, −16.0 to 36.0 | 10.00, 13.04, −16 to 29.0 | Group | 3.30 (2) | 0.19 | ||
| IGT attention to reward | 0.46, 0.39, 0–1.0 | 0.41, 0.33, 0–1.0 | Group | 0.09 (2) | 0.96 | ||
| IGT memory for past relative to recent outcomes | 0.37, 0.39, 0–1.0 | 0.22, 0.69, 0–1.0 | Group | 1.14 (2,57) | 0.33 | ||
| IGT choice consistency | 0.14, 2.58, −5.0 to 5.0 | 0.41, 2.06, −5 to 3.39 | Group | 0.45 (2,57) | 0.64 | ||
GMV: grey matter volume, IGT: Iowa Gambling Task, OFC: orbitofrontal cortex.
Significant reduction in symptom severity at follow-up.
Group comparisons based on pre-therapy IGT performance in 21 CBTp+SC patients and 21 healthy participants.
Kruskal–Wallis test performed due to heterogeneity of variance between groups.
Partial correlations (p) between OFC grey matter volume or OFC asymmetry and residual symptom change and IGT performance after covarying for whole brain volume and/or age.
| CBTp+SC group | Healthy participant group | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline ROI variable | Total | Left | Right | Asymmetry | Total | Left | Right | Asymmetry |
| PANSS Total | 0.302 | – | – | – | – | |||
| PANSS Positive | 0.308 | – | – | – | – | |||
| PANSS Negative | 0.306 | 0.146 | 0.379 | – | – | – | – | |
| PANSS General psychopathology | 0.347 | 0.209 | – | – | – | – | ||
| Pre-therapy IGT overall learning | 0.177 | 0.126 | 0.253 | 0.280 | 0.074 (0.38) | −0.008 (0.49) | 0.161 (0.26) | |
| Pre-therapy IGT attention to reward | − | − | −0.351 | −0.061 | −0.050 (0.42) | −0.085 (0.37) | −0.010 (0.48) | 0.160 (0.26) |
| Pre-therapy IGT memory for past relative to recent outcomes | −0.087 | −0.121 | −0.075 | 0.051 | 0.215 (0.20) | 0.216 (0.19) | 0.286 (0.12) | −0.034 (0.44) |
| Pre-therapy IGT choice consistency | −0.100 | −0.090 | −0.077 | −0.023 | − | − | − | 0.035 (0.44) |
Partial correlations were performed between OFC GMV and PANSS total and subscale scores and IGT performance while covarying for whole brain volume and age; partial correlations were performed between OFC rightward asymmetry and PANSS total and subscale scores and IGT performance while covarying for age.
Correlations based on 21 CBTp+SC patients and 21 healthy participants.
Spearman partial correlation was performed for IGT memory for past relative to recent outcomes because data transformation could not normalize data.
Fig. 2Scatter plot of right OFC grey matter volume in CBTp+SC patients with (a) PANSS total symptom change and (b) PANSS positive symptom change.